MONTREAL, March 23, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of its study on the immunostimulatory properties of its nucleic acid polymer (NAP technology) in the journal Scientific Reports (http://www.nature.com/articles/srep43838?WT.feed_name=subjects_immunology).
This study, conducted in collaboration with Dr. Ruth Broering’s group at the University Hospital at the University of Duisburg-Essen, reports on the immunostimulatory properties of clinically active NAPs in various liver and blood cells from non-infected human donors and shows that, even at high concentrations exceeding those present during therapy in clinical trials, that NAPs do not have any detectable immunostimulatory activity. “This study is the first published in a series of studies designed to improve our understanding of NAP pharmacology” said Dr. Andrew Vaillant, CSO “and allow us to focus our research efforts on identifying the molecular target(s) underlying the inhibition of HBsAg release by NAPs”.
Dr. Michel Bazinet, CEO, further commented “These results further demonstrate that the improved immune function and response to immunotherapy observed in patients receiving NAP-based combination therapy are driven by the clearance of HBsAg and not from direct exposure to NAPs”.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.